{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:45:43Z","timestamp":1780699543407,"version":"3.54.1"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is a rare X-linked genetic muscle disorder affecting primarily pediatric males and leading to limited life expectancy. This systematic review of 85 DMD trials and non-interventional studies (2010\u20132022) evaluated how magnetic resonance imaging biomarkers\u2014particularly fat fraction and T2 relaxation time\u2014are currently being used to quantitatively track disease progression and how their use compares to traditional mobility-based functional endpoints. Imaging biomarker studies lasted on average 4.50 years, approximately 11 months longer than those using only ambulatory functional endpoints. While 93% of biologic intervention trials (n\u2009=\u200928) included ambulatory functional endpoints, only 13.3% (n\u2009=\u20094) incorporated imaging biomarkers. Small molecule trials and natural history studies were the predominant contributors to imaging biomarker use, each comprising 30.4% of such studies. Small molecule trials used imaging biomarkers more frequently than biologic trials, likely because biologics often target dystrophin, an established surrogate biomarker, while small molecules lack regulatory-approved biomarkers. Notably, following the 2018 FDA guidance finalization, we observed a significant decrease in new trials using imaging biomarkers despite earlier regulatory encouragement. This analysis demonstrates that while imaging biomarkers are increasingly used in natural history studies, their integration into interventional trials remains limited. From XGBoost machine learning analysis, trial duration and start year were the strongest predictors of biomarker usage, with a decline observed following the 2018 FDA guidance. Despite their potential to objectively track disease progression, imaging biomarkers have not yet been widely adopted as primary endpoints in therapeutic trials, likely due to regulatory and logistical challenges. Future research should examine whether standardizing imaging protocols or integrating hybrid endpoint models could bridge the regulatory gap currently limiting biomarker adoption in therapeutic trials.<\/jats:p>","DOI":"10.1177\/22143602251360664","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T08:43:49Z","timestamp":1753778629000},"page":"525-534","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8044-5362","authenticated-orcid":false,"given":"Matthew","family":"Todd","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-7479","authenticated-orcid":false,"given":"Sanghoon","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunwen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9652-0129","authenticated-orcid":false,"given":"Devanand","family":"Adhin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-8811","authenticated-orcid":false,"given":"Deok Yong","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-0759","authenticated-orcid":false,"given":"Rebecca","family":"Willcocks","sequence":"additional","affiliation":[{"name":"Department of Physical Therapy, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0735","authenticated-orcid":false,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.12.012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00825-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.59"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004347"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002891"},{"key":"e_1_3_2_7_2","unstructured":"Ascadi G. Duchenne Muscular Dystrophy - Symptoms Causes Treatment | NORD https:\/\/rarediseases.org\/rare-diseases\/duchenne-muscular-dystrophy\/ (accessed 29 April 2024)."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009012"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10091547"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170344"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51933"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-024-09910-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13021"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201163"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23905"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24599"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162542"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000775"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-016-9109-x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239064"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12213"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14361"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199223"},{"key":"e_1_3_2_25_2","volume-title":"About biomarkers and qualification","author":"Center for Drug Evaluation and Research","year":"2024","unstructured":"Center for Drug Evaluation and Research. About biomarkers and qualification. Silver Spring, MD, USA: U.S. Food and Drug Administration, https:\/\/www.fda.gov\/drugs\/biomarker-qualification-program\/about-biomarkers-and-qualification (2024, accessed 4 March 2025)."},{"key":"e_1_3_2_26_2","volume-title":"Surrogate endpoint resources for drug and biologic development","author":"Center for Drug Evaluation and Research","year":"2024","unstructured":"Center for Drug Evaluation and Research. Surrogate endpoint resources for drug and biologic development. Silver Spring, MD, USA: U.S. Food and Drug Administration, https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development (2024, accessed 4 March 2025)."},{"key":"e_1_3_2_27_2","unstructured":"FDA. Duchenne muscular dystrophy and related dystrophinopathies: Developing drugs for treatment; draft guidance for industry."},{"key":"e_1_3_2_28_2","unstructured":"FDA. Rare diseases: Considerations for the development of drugs and biological products. Rare Dis."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080785"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00036-X"},{"key":"e_1_3_2_31_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_2_32_2","unstructured":"FDA. Duchenne muscular dystrophy and related dystrophinopathies: Developing drugs for treatment guidance for Industr https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-treatment-guidance (2018)."}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251360664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602251360664","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602251360664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:59:14Z","timestamp":1780549154000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602251360664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/22143602251360664"],"URL":"https:\/\/doi.org\/10.1177\/22143602251360664","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}